|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2100042166 |
|
最近更新日期: Date of Last Refreshed on: |
2021-04-10 01:46:09 |
|
注册时间: Date of Registration: |
2021-01-14 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
促动力药维持治疗功能性消化不良的临床疗效与安全性:一项真实世界研究 |
|
Public title: |
Clinical efficacy and safety of prokinetic agents as maintenance therapy for functional dyspepsia (FD): a real world study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
促动力药维持治疗功能性消化不良的临床疗效与安全性:一项真实世界研究 |
|
Scientific title: |
Clinical efficacy and safety of prokinetic agents as maintenance therapy for functional dyspepsia (FD): a real world study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
陈洁 |
研究负责人: |
侯晓华 |
|
Applicant: |
Jie Chen |
Study leader: |
Xiaohua Hou |
|
申请注册联系人电话: Applicant telephone: |
+86 18771001812 |
研究负责人电话:
Study leader's |
+86 15802734363 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
jie_chen_33@foxmail.com |
研究负责人电子邮件: Study leader's E-mail: |
houxh@hust.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
湖北省武汉市江汉区解放大道1277号华中科技大学同济医学院附属协和医院消化内科 |
研究负责人通讯地址: |
湖北省武汉市江汉区解放大道1277号华中科技大学同济医学院附属协和医院消化内科 |
|
Applicant address: |
Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Road, Wuhan, China. |
Study leader's address: |
Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Road, Wuhan, China. |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
华中科技大学同济医学院附属协和医院消化内科 |
||
|
Applicant's institution: |
Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
||
|
研究负责人所在单位: |
华中科技大学同济医学院附属协和医院消化内科 |
||
|
Affiliation of the Leader: |
Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
[2020]伦审字(0552)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
华中科技大学同济医学院附属协和医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
1990-01-01 00:00:00 | ||
|
伦理委员会联系人: |
吴建才 |
||
|
Contact Name of the ethic committee: |
Jiancai Wu |
||
|
伦理委员会联系地址: |
湖北省武汉市江汉区解放大道1277号 |
||
|
Contact Address of the ethic committee: |
1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
华中科技大学同济医学院附属协和医院消化内科 |
||||||||||||||||||||||
|
Primary sponsor: |
Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
湖北省武汉市江汉区解放大道1277号华中科技大学同济医学院附属协和医院消化内科 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
中国健康促进基金会 |
||||||||||||||||||||||
|
Source(s) of funding: |
China Health Promotion Foundation |
||||||||||||||||||||||
|
研究疾病: |
功能性消化不良 |
||||||||||||||||||||||
|
Target disease: |
functional dyspepsia |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
上市后药物 | ||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||
|
研究设计: |
非随机对照试验 |
||||||||||||||||||||||
|
Study design: |
Non randomized control |
||||||||||||||||||||||
|
研究目的: |
1.评价促动力药治疗FD及FD合并重叠症状患者的临床疗效与安全性; 2.了解FD及FD合并重叠症状患者的促动力药物治疗现状,如用药选择、疗程规范等; 3.了解功能性消化不良(FD)及FD合并重叠症状患者的流行病学相关信息。 |
||||||||||||||||||||||
|
Objectives of Study: |
1.To evaluate the clinical efficacy and safety of prokinetic agents in the treatment of FD patients with or without overlapping symptoms. 2.To investigate the status of treatment with prokinetic agents in FD patients with or without overlapping symptoms, such as drug selection, course of treatment, etc. 3.To explore the epidemiological characteristics of FD patients with or without overlapping symptoms. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
采用功能性胃肠病罗马IV功能性消化不良诊断标准。即具有餐后饱胀不适、早饱不适感、中上腹痛、中上腹烧灼感四个症状中的一项或多项,伴或不伴餐后中上腹胀气、恶心和嗳气,且常规检查和内镜检查未发现能够解释症状的其他器质性、全身性或代谢性疾病的证据,诊断前症状出现至少6个月,近3个月符合以上诊断标准。以上症状若在排便或排气后缓解,则一般不诊断为功能性消化不良。初治及经治患者使用促动力药物进行治疗(包括多潘立酮、莫沙必利、伊托必利、西尼必利等)。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Rome IV diagnostic criteria for functional dyspepsia are adopted. |
||||||||||||||||||||||
|
排除标准: |
精神病患者和智力、语言障碍者;明确对此类药物或其组成成份过敏者;存在消化道报警症状者(不明原因的体重减轻、反复呕吐、进行性加重的吞咽困难、呕血、黑便等);幽门螺杆菌相关性消化不良(幽门螺杆菌阳性,及幽门螺杆菌根除治疗后未满12个月的患者);已明确的由NSAIDs或其他药物引起的消化不良;其他严重器质性、全身性或代谢性疾病;根据研究者的判断、具有降低入组可能性或使入组复杂化的其他情况,如工作环境经常变动等易造成失访的情况。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Patients with mental and language disorders; patients who are allergic to prokinetic drugs or their components; patients who have gastrointestinal alarm symptoms: unexplained weight loss, repeated vomiting, progressive dysphagia, hematemesis, melena, etc.; Helicobacter pylori associated dyspepsia (positive results for Helicobacter pylori test, or less than 12 months after Helicobacter pylori eradication; dyspepsia caused by NSAIDs or other drugs; other serious organic, systemic or metabolic diseases; other situations that may add difficulties to enrollment or follow-up, such as frequent changes in the working places. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2021-02-01 00:00:00至 To 2021-11-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2021-03-01 00:00:00 至 To 2021-06-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
不适用 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Not applicable |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
于项目完成后6个月公开于本平台 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
6 months after the completion of the project on this platform |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
由病例记录表采集 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
using case record form |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |